Julian Gangolli

Mr. Gangolli became a member of the Board of Directors in April 2020. He is deeply experienced in pharmaceutical commercialization, having served as President of the North American Pharmaceutical division of Allergan, Inc. for 11 years where he was a member of the Executive Committee of Allergan and was responsible for a 1,400-person commercial operation with sales exceeding $3.8 billion in 2014.

Mr. Gangolli most recently served as President, North America of Greenwich Biosciences, a GW Pharmaceuticals PLC company, where he was responsible for building out the U.S. commercial infrastructure and spearheading the launch of its lead therapeutic product, Epidiolex.® Prior to that, Mr. Gangolli joined Allergan in 1998 as a senior member of the management team that transformed the company into one of the leading specialty pharmaceutical firms in the United States. As a member of the Allergan Executive Committee, he was part of the select team that executed the sale of Allergan to Actavis in 2015.

Mr. Gangolli also currently serves as a Director on the Board of two publicly-traded pharmaceutical companies: Revance Therapeutics (NASDAQ: RVNC) and Krystal Biotech (NASDAQ: KRYS).

Mr. Gangolli received his BSc with Honors in applied chemistry from Kingston University, Kingston-Upon-Thames, Surrey, UK.